Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 135.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 135.
Brown Adipose Tissue and Estrogen (BATE Study) 13-0149
To investigate whether estrogen influences the activity of brown adipose tissue.
Healthy non-smoking women 20-40 who have regular menstrual cycles and are not on hormonal contraceptives and exercise more than once per week
PI: Melanson, Edward
  • 720-848-6399
  • Kimberly.Harner@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 11-0909
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
PI: Huebschmann, Amy
  • 303-724-2255
  • Ian.Leavitt@ucdenver.edu
Are you stopping your birth control because you want to become pregnant? 13-1594
To look at contraception rates after birth control discontinuation.
Women 18-35 who are planning to, or have recently stopped their birth control because they want to become pregnant.
PI: Teal, Stephanie
  • 303-724-2013
  • Sandra.cano@ucdenver.edu
Type 1 Diabetes Research Study 11-0649
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
Is your child 6-18 years old and interested in participating in a research study? 13-2073
To study the effects of polycystic kidney disease (PKD) on blood vessel function
Children 6-22 free from kidney disease and other chronic diseases
PI: Jablonski, Kristin
  • 303-724-7791
  • Heather.Farmer@ucdenver.edu
Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Lipohypertrophy Study 13-2759
This study is looking at evaluating Insulin Pump Infusion sites and Continuous Glucose Monitoring sites in tissue with Lipohypertrophy. We will also be looking at using the sites for a longer duration.
Lipohypertrophy site of 3 cm or greater in diameter Ages 12-45 inclusive A1C Value of < 10% Insulin pump use of at least 3 month duration Pump use with Medtronic, Animas or T-slim Willing to wear two CGM's during the 4 weeks of the study
PI: Maahs, David
  • 303-724-6742
  • Sally.Sullivan@ucdenver.edu
JUST DIAGNOSED WITH SHINGLES? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
protein and infant growth: Do you have a child younger than 6 months 14-0139
Participants in this research study on protein from complementary foods (meat or dairy) and infant growth, will learn how protein consumption affects your child’s growth, fat gain, and gut health from 6 to 12 months of age.  
To qualify, you child needs to be: 1. Formula fed, or not on breast-milk longer than 1 month. 2. Younger than 6 months. 3. Generally healthy. You will receive commercially available complementary foods for 7 months, Receive infant formula at no cost for 7 months, You will know your child's body fat and fat free mass and blood lipid level.
PI: Krebs, Nancy
  • 303-724-3248
  • minghua.tang@ucdenver.edu
Volunteers Needed: Thinking and Memory in Parkinson's Disease 13-2724
This research study aims to better understand how changes in brain activity may be related to thinking problems in Parkinson's Disease and to determine whether, by stimulating certain areas, thinking and memory can be improved.
Person's with Parkinson's Disease with mild thinking and memory problems. Between 40-90 years old. No metal in your body. No implant. Not taking any medication to improve memory. Not taking stimulants or seizure medication.
PI: Kluger, Benzi
  • 303-724-5973
  • mailto:isabelle.buard@ucdenver.edu
Participants Ages 12-15 years old Needed for Research Study 04-0311
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
PI: Levisohn, Paul
  • 720-777-8608
  • Nanastasia.Welnick@childrenscolorado.org
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls 13-2927
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
A relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years

OR

A healthy individual 18-55 years old without Multiple Sclerosis or other neurological conditions
PI: Miravalle, Augusto
  • 303-724-8388
  • Eric.Engebretson@ucdenver.edu
Research Participants Needed 14-0770
We are looking for participants with diabetes to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria: 1) 50-85 years of age. 2) Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking). 3) Diagnosis of diabetes. 4) No other neurological, vascular or cardiac problems that limit function. 5) Body mass index
PI: Christiansen, Cory
  • 303-724-9590
  • Amanda.murray@ucdenver.edu
Healthy Hispanic Female Adolescents Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity.
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions or permanent metal implants or braces/retainers and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
HAVE YOU OR YOUR CHILD BEEN DIAGNOSED WITH ASTHMA? HS-2827
We are looking for volunteers to participate in an N.I.H. funded research study.
Children 12 years of age and older and non-smoking Adults who have mild to moderate asthma who are not currently taking inhaled steroid medication
PI: Martin, Richard
  • 303-398-1443
  • martinlab@njhealth.org
Do You or Someone You Know Suffer From Relapse Remitting Multiple Sclerosis (RRMS)? 13-2209
The University of Colorado Denver is conducting a clinical trial to evaluate the effectiveness, safety and tolerability of two doses of oral administration of laquinimod in subjects with Relapse Remitting Multiple Sclerosis (RRMS). Patients that suffer from RRMS may experience a gradual increase of their disability over time. The purpose of this study is to find out whether laquinimod is safe and effective in slowing the rate of disability progression.
-Between the ages of 18 and 55 -Have clinically confirmed diagnosis of Multiple Sclerosis (MS) with relapse onset disease or relapsing-remitting disease course -Have had at least one documented relapse within 12 months prior to starting this study -Have not been treated with Natalizumab (Tysabri) or Rituximab 2 years prior to starting this study
PI: Vollmer, Timothy
  • 303-724-6351
  • Nicola.Haakonsen@ucdenver.edu
Participants Needed for an Exercise Study for People with Multiple Sclerosis 14-0295
Researchers from the Neurophysiology of Movement Laboratory on the University of Colorado Boulder campus and the Multiple Sclerosis Center on the University of Colorado Anschutz Medical Campus are conducting a study to investigate the capacity of neuromuscular electrical stimulation to improve walking in persons with multiple sclerosis.
-Between 18 to 55 years of age -Have clinically confirmed diagnosis of MS -Are able to talk but have some difficulty walking
PI: Enoka, Roger
  • 303-724-4644
  • Roger.Enoka@colorado.edu
Sedentary Behavior Research Study 14-0429
This research study plans to learn more about how the time we spend seated affects your health
Healthy male and female Age: 19-45 With BMI: 27-33 you may check this at: http://nhlbisupport.com/bmi/ Be seated more than 6hr/d Be physically active on less than 3-4 days/wk
PI: Bergouignan, Audrey
  • 303-724-9026
  • nathan.dejong@ucdenver.edu
Healthy Minority Volunteers Needed 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
Documented negative testing for HIV and hepatitis B Not at risk for HIV Study population balanced by Caucasian, African-American, Hispanic race. African American and Hispanic participants are currently needed. Age 18-50 years Able to meet study personnel on Anschutz Medical Campus for directly observed dosing with study medication, or by audio-visual communication with a mobile cellular device when off Campus
PI: Anderson, Peter
  • 303-724-8296
  • Kayla.bushman@ucdenver.edu
University of Colorado Recruiting Patients for a Clinical Research Study for Psoriasis 13-2720
The research study compares the effect of treatments, such as Humira and phototherapy, on inflammation in the body and cardiovascular disease. This study will look for systemic vascular inflammation in subjects enrolled in this study, with a test called FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography computed tomography).
We are looking for males and females 18 years of age and older with a diagnosis of psoriasis for at least 6 months
PI: Armstrong, April
  • 720-848-3607
  • aleksandra.florek@ucdenver.edu
HIV-V-A004 - Learn More About A Clinical Research Study For Investigational HIV Vaccines. 14-2056
The purpose of this study is to assess the safety and immune system response to investigational HIV vaccines in healthy, HIV-uninfected adult volunteers. These assessments will help researchers plan future vaccine studies.
- Willing to participate and who understand the purpose and procedures of the study „- 18 – 50 years of age „- HIV-uninfected „- In good health „- Willing to maintain behavior consistent with low risk HIV exposure
PI: Campbell, MD, Thomas
  • 303-724-0801
  • dana.momeyer@ucdenver.edu
Healthy Adolescents Needed 07-0709
Psychological study on how flexible your brain can shift from one task to another.
-Female -age 12-17 years old -in good health -on no medication
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Help test a mobile app for postpartum moms 14-1173
This research study will test a mobile application to learn more about how to best deliver information about diet and physical activity for postpartum women at elevated risk for diabetes and heart disease.
You may qualify for this study if you:  Are between 18-45 years old  Are in your third trimester of pregnancy or have given birth in the last 24 weeks  Have a postpartum BMI: 25-45 kg/m2  Have access to and be willing to use a wi-fi enabled iPhone or an iPod  Have a history of one or more of the following complications in your most recent pregnancy: o Gestational diabetes mellitus o Preeclampsia o Gestational hypertension o Pre-term delivery (32-37) weeks o Small for gestational age (
PI: Nicklas , Jacinda
  • 303-724-8898
  • jessica.jaramillo@ucdenver.edu
Diabetic Male and Female Volunteers Needed for Exercise Research Study 06-0062
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
PI: Regensteiner, Judith
  • 303-724-2255
  • katie.rogers@ucdenver.edu
Trouble Controlling your Type 2 Diabetes? 12-1529
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
PI: Wyatt, Holly
  • GI Dynamics
  • Jeanneanne.breen@ucdenver.edu
Project Safe - THE IMPACT OF MEDICAL MARIJUANA IN METROPOLITAN DENVER 11-0718
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
PI: Booth, Robert
  • 1-800-429-9240
  • Eric.Kovalsky@ucdenver.edu
Persons with active, moderate to severe ulcerative colitis needed 12-1408
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
PI: Gerich, Mark
  • 303-724-7875
  • katelyn.cowan@ucdenver.edu
3D Gait Analysis Participants Needed 13-1857
Research study investigating the coordination of walking
Subject with Spastic Cerebral Palsy Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Retrospective gait data must contain a complete lower body marker set and valid kinetic data. ● Only gait data trials of the subject walking unassisted will be used. ● Diagnosis of spastic cerebral palsy. ● Exhibits either stiff knee gait pattern, characterized by insufficient and delayed peak knee flexion during swing (less than 45), or crouch gait pattern, characterized by excessive hip flexion and knee flexion (greater than 30 throughout stance). Cerebellar Ataxic Gait Subject Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Diagnosis of either Friedreich's or spinocerebellar ataxia. Subject with Lower Limb Amputation Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Has been using the prosthetic limb for at least 6 months for independent ambulation prior to gait analysis at CGMA. ● Below knee or above knee amputation.
PI: Worster, Kate
  • 720-777-8216
  • worsterk@gmail.com
Would you like to participate in a study to improve the understanding of how emotions and symptom distress affect adherence to hormonal therapy in breast cancer? 13-0371
The purpose of this study is to understand how emotional factors and symptom distress affect adherence to hormonal therapy in women that have completed all other treatment for breast cancer.   
Women Breast Cancer Survivor Age 21-70 years old Within 24 months of starting hormonal therapy: Aromatase Inhibitors or Tamoxifen (Aromatase Inhibitors, Exemestane (aromasin), Letrolzole (Femara), Anastrozole (Arimidex).
PI: Grossman, Vicki
  • 720-352-3316
  • Vicki.Grossman@ucdenver.edu
Pharmacokinetics Research Study of Nontuberculous Mycobacteria Antibiotics in HEALTHY people and in people with CYSTIC FIBROSIS 14-1043
We are conducting a research study to test if levels of antibiotics used to treat nontuberculous mycobacteria infections are different between people with and without cystic fibrosis. The goal of our study is to provide recommendations for treatment of CF patients with lung disease due to nontuberculous mycobacterial infection.
Teenagers and adults who are either healthy or who have cystic fibrosis and are 16 to 45 years old may be eligible to participate in this study.
PI: Martiniano, Stacey
  • 720-777-2945
  • Meg.Anthony@childrenscolorado.org
Have the Flu? Living with a chronic medical condition, too? 11-0101
Influenza (the flu) can be life-threatening. Approximately 24,000 people in the United States die each year of this disease. We are conducting a study to determine whether treating patients with a combination of several drugs instead of just one helps them to get better faster.
You qualify for our study if you: •Have been diagnosed with the flu •Are at least 18 years of age •Have an existing medical condition that puts you at increased risk for complications from the flu—conditions such as diabetes; heart, lung, and kidney disease; COPD; and asthma
PI: Barron, Michelle
  • 303-724-0712
  • Graham.Ray@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 557.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 557.
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy” – Sponsor SOTIO Sponsor Protocol No. SP005 WIRB Protocol No. 20141765
Flaig, Thomas13-2709
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer Sponsor Protocol No. INCB 18424-268 WIRB Protocol No. 20141874
Elias, Anthony14-0356
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James14-0383
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
A PHASE 1B, DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF PF-06342674 (RN168) IN SUBJECTS WITH MULTIPLE SCLEROSIS (MS) Sponsor Protocol No. B4351002 WIRB Protocol No. 20141635
Vollmer, Timothy14-0555
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction with Midazolam, and Safety and Tolerability in Patients with Advanced Malignancies Sponsor Protocol No. OPZ009 WIRB Protocol No. 20141700
Gore, Lia14-0589
Evaluation of the Effectiveness of Evolution® Biliary Stent System – Fully Covered. Sponsor Protocol No. 10-014. WIRB Protocol No. 20142167
Shah, Raj14-0602
RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE−POSITIVE ADVANCED NON−SMALL CELL LUNG CANCER Sponsor Protocol No. BO28984 WIRB Protocol No. 20140921
Camidge, David14-0643
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Sponsor Protocol No. M12-914 WIRB Protocol No. 20141072
Borges, Virginia14-0799
A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects with Adult Solid Tumors. Sponsor Protocol No. LOXO-TRK-14001. WIRB Protocol No. 20142018
Doebele, Robert14-0886
PROspective Study of the IMPACT of Decipher® Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions following Radical Prostatectomy [PRO-IMPACT] Sponsor Protocol No. CU004 WIRB Protocol No. 20142208
Maroni, Paul14-0910
A Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Sponsor Protocol No. CD-IA-MEDI-551-1155 WIRB Protocol No. 20142285
Bennett, Jeffrey14-0926
A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy. Sponsor Protocol No. ALDOXORUBICIN-PE-STS-01. WIRB Protocol No. 20141245
Elias, Anthony14-1004
CEP292- A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 hours (7days) of Use. Sponsor Protocol No. CEP292/Z25/B. WIRB Protocol No. 20140632
Slover, Robert14-1039
A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 Hours (7 Days) of Use Study Sponsor Protocol No. CEP292/Z25/B WIRB Protocol No. 20140632
Garg, Satish14-1040
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies Sponsor Protocol No. ORTE-01-14-US WIRB Protocol No. 20141629
Jimeno, Antonio14-1055
A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are &ge; 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy Sponsor Protocol No. M14-358 WIRB Protocol No. 20141655
Pollyea, Daniel14-1142
A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of Head and Neck, Lung, or Esophagus. Sponsor Protocol No. KCP-330-006. WIRB Protocol No. 20141119
Jimeno, Antonio14-1152
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors Sponsor Protocol No. CLC-101 WIRB Protocol No. 20141911
Eckhardt, Sue14-1201
A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the Eye Sponsor Protocol No. 32-007 WIRB Protocol No. 20111432
Palestine, Alan14-1279
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION. Sponsor Protocol No. GX29185. WIRB Protocol No. 20141609
Oliver, Scott14-1281
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB). Sponsor Protocol No. M14-227. WIRB Protocol No. 20141710
Everson, Greg14-1284
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RPC4046 IN ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS. Sponsor Protocol No. RPC02-201. WIRB Protocol No. 20140555
Menard-Katcher, Paul14-1285
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS). Sponsor Protocol No. 101MS409. WIRB Protocol No. 20141062
Alvarez, Enrique14-1295
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC) Sponsor Protocol # C26002 WIRB Protocol # 20141183
Messersmith, Wells14-1305
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC). Sponsor Protocol No. C26003. WIRB Protocol No. 20141223
Messersmith, Wells14-1306


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more